Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Glioma | Research

Mir-139-5p inhibits glioma cell proliferation and progression by targeting GABRA1

Authors: Lei Wang, Yan Liu, Zhengtao Yu, Jianwu Gong, Zhiyong Deng, Nianjun Ren, Zhe Zhong, Hao Cai, Zhi Tang, Haofeng Cheng, Shuai Chen, Zhengwen He

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Glioma is an extremely aggressive malignant neoplasm of the central nervous system. MicroRNA (miRNA) are known to bind to specific target mRNA to regulate post-transcriptional gene expression and are, therefore, currently regarded as promising biomarkers for glioma diagnosis and prognosis. The aim of the present study was to examine the pathogenesis and potential molecular markers of glioma by comparing the differential expression of miRNA and mRNA between glioma tissue and peritumor brain tissue. We explored the impact of screened core miRNA and mRNA on cell proliferation, invasion, and migration of glioma. An miRNA expression profile dataset (GSE90603) and a transcriptome profile dataset (GSE90598) were downloaded from combined miRNA-mRNA microarray chips in the Gene Expression Omnibus (GEO) database. Overall, 59 differentially expressed miRNAs (DEMs) and 419 differentially expressed genes (DEGs) were identified using the R limma software package. FunRich software was used to predict DEM target genes and miRNA-gene pairs, and Perl software was used to find overlapping genes between DEGs and DEM target genes. There were 129 overlapping genes regulated by nine miRNAs between target genes of the DEMs and DEGs. The Chinese Glioma Genome Atlas(CGGA) was analyzed in order to identify miRNAs with diagnostic and prognostic significance. MiR-139-5p, miR-137, and miR-338-3p were validated to be significantly linked to prognosis in glioma patients. Finally, we validated that miR-139-5p affected glioma malignant biological behavior via targeting gamma-aminobutyric acid A receptor alpha 1(GABRA1) through rescue experiments. Low miR-139-5p expression was correlated with survival probability and World Health Organization (WHO) grade. MiR-139-5p overexpression inhibited cell proliferation, migration, and invasion of glioma in vitro. GABRA1 was identified as a functional downstream target of miR-139-5p. Decreased GABRA1 expression was related to similar biological roles as miR-139-5p overexpression while upregulation of GABRA1 effectively reversed the inhibition effects of miR-139-5p. These results demonstrate a novel axis for miR-139-5p/GABRA1 in glioma progression and provide potential prognostic predictors and therapeutic target for glioma patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRef Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRef
2.
go back to reference Sadetzki S, Zach L, Chetrit A, Nass D, Hoffmann C, Ram Z, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008;31:264–9.CrossRef Sadetzki S, Zach L, Chetrit A, Nass D, Hoffmann C, Ram Z, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008;31:264–9.CrossRef
3.
go back to reference Huang J, Samson P, Perkins SM, Ansstas G, Chheda MG, DeWees TA, et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol. 2017;131:593–601.CrossRef Huang J, Samson P, Perkins SM, Ansstas G, Chheda MG, DeWees TA, et al. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol. 2017;131:593–601.CrossRef
4.
go back to reference Anton K, Baehring JM, Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 2012;26:825–53.CrossRef Anton K, Baehring JM, Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 2012;26:825–53.CrossRef
5.
go back to reference Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.CrossRef Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.CrossRef
6.
go back to reference Zhou Q, Liu J, Quan J, Liu W, Tan H, Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis. Cancer Sci. 2018;109:2651–9.CrossRef Zhou Q, Liu J, Quan J, Liu W, Tan H, Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis. Cancer Sci. 2018;109:2651–9.CrossRef
7.
go back to reference Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601.CrossRef Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601.CrossRef
8.
go back to reference Zhou F, Cao W, Xu R, Zhang J, Yu T, Xu X, et al. MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA. Am J Transl Res. 2019;11:4584–601.PubMedPubMedCentral Zhou F, Cao W, Xu R, Zhang J, Yu T, Xu X, et al. MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA. Am J Transl Res. 2019;11:4584–601.PubMedPubMedCentral
9.
go back to reference Xin, S., Huang, K., Zhu, X. G., Non-coding RNAs: Regulators of glioma cell epithelial-mesenchymal transformation, Pathol. Res. Pract. (2019) 215:152539. Xin, S., Huang, K., Zhu, X. G., Non-coding RNAs: Regulators of glioma cell epithelial-mesenchymal transformation, Pathol. Res. Pract. (2019) 215:152539.
10.
go back to reference Yang H, Song Z, Wu X, Wu Y, Liu C. MicroRNA-652 suppresses malignant phenotypes in glioblastoma multiforme via FOXK1-mediated AKT/mTOR signaling pathway. Onco Targets Ther. 2019;12:5563–75.CrossRef Yang H, Song Z, Wu X, Wu Y, Liu C. MicroRNA-652 suppresses malignant phenotypes in glioblastoma multiforme via FOXK1-mediated AKT/mTOR signaling pathway. Onco Targets Ther. 2019;12:5563–75.CrossRef
11.
go back to reference Zuo J, Yu H, Xie P, Liu W, Wang K, Ni H. miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma. Gene. 2019;710:233–9.CrossRef Zuo J, Yu H, Xie P, Liu W, Wang K, Ni H. miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma. Gene. 2019;710:233–9.CrossRef
12.
go back to reference Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019;38:133.CrossRef Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019;38:133.CrossRef
13.
go back to reference Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs. 2012;21:1475–88.CrossRef Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs. 2012;21:1475–88.CrossRef
14.
go back to reference Yin J, Lin J, Luo X, Chen Y, Li Z, Ma G, et al. miR-137: a new player in schizophrenia. Int J Mol Sci. 2014;15:3262–71.CrossRef Yin J, Lin J, Luo X, Chen Y, Li Z, Ma G, et al. miR-137: a new player in schizophrenia. Int J Mol Sci. 2014;15:3262–71.CrossRef
15.
go back to reference Kos A, Aschrafi A, Nadif KN. The multifarious hippocampal functions of MicroRNA-137. Neuroscientist. 2016;22:440–6.CrossRef Kos A, Aschrafi A, Nadif KN. The multifarious hippocampal functions of MicroRNA-137. Neuroscientist. 2016;22:440–6.CrossRef
16.
go back to reference Wu L, Chen J, Ding C, Wei S, Zhu Y, Yang W, et al. MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2. PLoS ONE. 2015;10:e0130124.CrossRef Wu L, Chen J, Ding C, Wei S, Zhu Y, Yang W, et al. MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2. PLoS ONE. 2015;10:e0130124.CrossRef
17.
go back to reference Sakaguchi M, Hisamori S, Oshima N, Sato F, Shimono Y, Sakai Y. miR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1. Mol Cancer Res. 2016;14:354–62.CrossRef Sakaguchi M, Hisamori S, Oshima N, Sato F, Shimono Y, Sakai Y. miR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1. Mol Cancer Res. 2016;14:354–62.CrossRef
18.
go back to reference Sun C, Li J. Expression of MiRNA-137 in oral squamous cell carcinoma and its clinical significance. J BUON. 2018;23:167–72.PubMed Sun C, Li J. Expression of MiRNA-137 in oral squamous cell carcinoma and its clinical significance. J BUON. 2018;23:167–72.PubMed
19.
go back to reference Zhang R, Shi H, Ren F, Liu Z, Ji P, Zhang W, et al. Down-regulation of miR-338-3p and Up-regulation of MACC1 indicated poor prognosis of epithelial ovarian cancer patients. J Cancer. 2019;10:1385–92.CrossRef Zhang R, Shi H, Ren F, Liu Z, Ji P, Zhang W, et al. Down-regulation of miR-338-3p and Up-regulation of MACC1 indicated poor prognosis of epithelial ovarian cancer patients. J Cancer. 2019;10:1385–92.CrossRef
20.
go back to reference Zhang P, Shao G, Lin X, Liu Y, Yang Z. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res. 2017;7:53–63.PubMedPubMedCentral Zhang P, Shao G, Lin X, Liu Y, Yang Z. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2. Am J Cancer Res. 2017;7:53–63.PubMedPubMedCentral
21.
go back to reference Sun F, Yu M, Yu J, Liu Z, Zhou X, Liu Y, et al. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018;9:522.CrossRef Sun F, Yu M, Yu J, Liu Z, Zhou X, Liu Y, et al. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018;9:522.CrossRef
22.
go back to reference Howe JR, Li ES, Streeter SE, Rahme GJ, Chipumuro E, Russo GB, et al. MiR-338–3p regulates neuronal maturation and suppresses glioblastoma proliferation. PLoS ONE. 2017;12:e0177661.CrossRef Howe JR, Li ES, Streeter SE, Rahme GJ, Chipumuro E, Russo GB, et al. MiR-338–3p regulates neuronal maturation and suppresses glioblastoma proliferation. PLoS ONE. 2017;12:e0177661.CrossRef
23.
go back to reference Nam RK, Benatar T. CJD, W, Kobylecky, E, Amemiya, Y, Sherman, C, et al, MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. Prostate. 2019;79:1422–38.CrossRef Nam RK, Benatar T. CJD, W, Kobylecky, E, Amemiya, Y, Sherman, C, et al, MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. Prostate. 2019;79:1422–38.CrossRef
24.
go back to reference Bai X, Lu D, Lin Y, Lv Y, He L. A seven-miRNA expression-based prognostic signature and its corresponding potential competing endogenous RNA network in early pancreatic cancer. Exp Ther Med. 2019;18:1601–8.PubMedPubMedCentral Bai X, Lu D, Lin Y, Lv Y, He L. A seven-miRNA expression-based prognostic signature and its corresponding potential competing endogenous RNA network in early pancreatic cancer. Exp Ther Med. 2019;18:1601–8.PubMedPubMedCentral
25.
go back to reference Wang X, Gao J, Zhou B, Xie J, Zhou G, Chen Y. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Life Sci. 2019;232:116596.CrossRef Wang X, Gao J, Zhou B, Xie J, Zhou G, Chen Y. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Life Sci. 2019;232:116596.CrossRef
26.
go back to reference Li P, Xiao Z, Luo J, Zhang Y, Lin L. MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1. J Cell Mol Med. 2019;23:2475–88.CrossRef Li P, Xiao Z, Luo J, Zhang Y, Lin L. MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1. J Cell Mol Med. 2019;23:2475–88.CrossRef
27.
go back to reference Yong-Hao Y, Xian-Guo W, Ming X, Jin-Ping Z. Expression and clinical significance of miR-139-5p in non-small cell lung cancer. J Int Med Res. 2019;47:867–74.CrossRef Yong-Hao Y, Xian-Guo W, Ming X, Jin-Ping Z. Expression and clinical significance of miR-139-5p in non-small cell lung cancer. J Int Med Res. 2019;47:867–74.CrossRef
28.
go back to reference Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun H, et al. miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 2015;36:6741–9.CrossRef Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun H, et al. miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 2015;36:6741–9.CrossRef
29.
go back to reference Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, et al. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 2013;19:477–83.CrossRef Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, et al. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 2013;19:477–83.CrossRef
30.
go back to reference Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573:532–8.CrossRef Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573:532–8.CrossRef
31.
go back to reference Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573:539–45.CrossRef Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573:539–45.CrossRef
32.
go back to reference Birnir B, Korpi ER. The impact of sub-cellular location and intracellular neuronal proteins on properties of GABA(A) receptors. Curr Pharm Des. 2007;13:3169–77.CrossRef Birnir B, Korpi ER. The impact of sub-cellular location and intracellular neuronal proteins on properties of GABA(A) receptors. Curr Pharm Des. 2007;13:3169–77.CrossRef
33.
go back to reference Young SZ, Bordey A. GABA’s control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda). 2009;24:171–85. Young SZ, Bordey A. GABA’s control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda). 2009;24:171–85.
34.
go back to reference D’Urso PI, D’Urso OF, Storelli C, Mallardo M, Gianfreda CD, Montinaro A, et al. miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol. 2012;41:228–34.PubMed D’Urso PI, D’Urso OF, Storelli C, Mallardo M, Gianfreda CD, Montinaro A, et al. miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol. 2012;41:228–34.PubMed
35.
go back to reference Smits A, Jin Z, Elsir T, Pedder H, Nistér M, Alafuzoff I, et al. GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. PLoS ONE. 2012;7:e37041.CrossRef Smits A, Jin Z, Elsir T, Pedder H, Nistér M, Alafuzoff I, et al. GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. PLoS ONE. 2012;7:e37041.CrossRef
36.
go back to reference Blanchart A, Fernando R, Häring M, Assaife-Lopes N, Romanov RA, Andäng M, et al. Endogenous GABAA receptor activity suppresses glioma growth. Oncogene. 2017;36:777–86.CrossRef Blanchart A, Fernando R, Häring M, Assaife-Lopes N, Romanov RA, Andäng M, et al. Endogenous GABAA receptor activity suppresses glioma growth. Oncogene. 2017;36:777–86.CrossRef
Metadata
Title
Mir-139-5p inhibits glioma cell proliferation and progression by targeting GABRA1
Authors
Lei Wang
Yan Liu
Zhengtao Yu
Jianwu Gong
Zhiyong Deng
Nianjun Ren
Zhe Zhong
Hao Cai
Zhi Tang
Haofeng Cheng
Shuai Chen
Zhengwen He
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02880-9

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.